Trial Profile
Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Jul 2021
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Jan 2018 Status changed from not yet recruiting to active, no longer recruiting, as reported in an abstract presented at the 2018 Gastrointestinal Cancers Symposium
- 20 Jan 2018 Results (n=30) presented at the 2018 Gastrointestinal Cancers Symposium
- 21 Aug 2015 New trial record